European Commission

A shortage of regulatory capacity continues to slow the implementation of the EU's In Vitro Diagnostic Regulation.

In a Statement of Objections, the agency laid out the intended divestment and transitional measures for Illumina to unwind and dissolve the Grail acquisition.

Separately, the US Federal Trade Commission said it will appeal an administrative law judge's initial decision in an antitrust case that was favorable to Illumina.